1
|
Abali H, Yalcin S, Onal C, Dane F, Oksuzoglu B, Ozdemir N, Mertsoylu H, Artac M, Camci C, Karabulut B, Basal FB, Budakoglu B, Sendur MAN, Goktas B, Ozdener F, Baygul A. A study of the combination of oxaliplatin, capecitabine, and trastuzumab and chemo-radiotherapy in the adjuvant setting in operated patients with HER2+ gastric or gastroesophageal junction cancer (TOXAG study). J Clin Oncol 2018. [DOI: 10.1200/jco.2018.36.4_suppl.26] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022] Open
Abstract
26 Background: We evaluated the safety and tolerability of trastuzumab (T) in combination with oxaliplatin (O), capecitabine (C) and chemo-radiotherapy in the adjuvant setting in operated, HER-2 positive gastric or gastroesophageal junction adenocarcinoma patients. Methods: We have screened 212 and enrolled 34 patients who were curatively resected (R0, R1 with partial or total gastrectomy, with D2 lymph node dissection) and were HER2-positive (IHC 2+/FISH+ or IHC 3+). The primary objectives were safety and tolerability of the treatment combination and secondary objectives were disease-free and overall survival rates. Patients received T 8 mg/kg intravenously (iv) on Day 1 of cycle 1 and 6 mg/kg iv on day 1 of every following 3-weekly cycle for 1 year as 17 cycles, O 100 mg/m2 iv on Day 1 of cycles 1-3 and C 850 mg/m2 orally twice daily on days 1-14 of cycles 1-3 and 5 days per week during chemo-radiotherapy. Radiotherapy was given at a total dose of 45 Gy divided into 25 doses 5 treatment days per week for 5 weeks starting from the 1st day of cycle 4. Results: The median age was 57 years and 73.5% were male, 97.0% had an ECOG PS score ≤ 1,33, 97.0% had D2 lymph node resection. Staging was 3A or higher at the time of diagnosis in 76.4% of patients. Patients had high rate of tolerability to the combination regimen (90.3%) and successfully completed 3 cycles of O+C+T plus chemoradiotherapy followed by continuation with T, achieving the primary goal of the study by showing a better tolerability rate as compared to tolerability reported for INT0116 study (p = 0.0068). After 25 months of follow-up confirmed through a telephone visit, 59.8% patients were still alive and median overall survival was not yet reached. Twelve patients died secondary to disease progression. There were no deaths due to toxicity and 6 dose reductions overall (1 for T, 2 for O and 3 for C). T was stopped in one patient; C was temporarily interrupted 11 times (mostly during radiotherapy) and stopped in 1 patient. Conclusions: T in combination with C, O and radiotherapy in the adjuvant setting for gastric or gastroesophageal junction adenocarcinoma seems safe and tolerable. Clinical trial information: NCT01748773.
Collapse
Affiliation(s)
| | | | - Cem Onal
- Baskent University, Adana, Turkey
| | | | - Berna Oksuzoglu
- Dr. A.Y. Ankara Oncology Training and Research Hospital, Ankara, Turkey
| | - Nuriye Ozdemir
- Ankara Numune Education and Research Hospital, Ankara, Turkey
| | | | - Mehmet Artac
- Necmettin Erbakan University Meram School of Medicine, Konya, Turkey
| | | | | | | | | | | | | | | | | |
Collapse
|
2
|
Aktas G, Kus T, Emin Kalender M, Kervancioglu S, Sevinc A, Kul S, Camci C. Sorafenib with TACE improves the survival of hepatocellular carcinoma patients with more than 10 cm tumor: a single-center retrospective study. J BUON 2017; 22:150-156. [PMID: 28365948] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/07/2023]
Abstract
PURPOSE Sorafenib, a multikinase inhibitor, is effective in patients with advanced hepatocellular carcinoma (HCC). Transarterial chemoembolization (TACE) is an important palliative treatment for unresectable HCC, but TACE-induced ischemic injury can upregulate angiogenic factors and it might be associated with poor prognosis. The purpose of this study was to evaluate the efficacy of conventional TACE with or without sorafenib in patients with Barcelona Clinic Liver Cancer (BCLC) stage A-B HCC. METHODS Thirty patients with BCLC stage A or B HCC who had undergone TACE were enrolled in this retrospective study. Child-Pugh score, BCLC staging classification, size and number of lesions were recorded. Sorafenib was given 1 month after TACE to some patients who responded to TACE. Repeated TACE was performed on demand. Tumor response was assessed every 12 weeks. The primary objective of this trial was the progression free survival (PFS). Secondary objectives were overall survival (OS), disease control rate (DCR) and total number of TACE interventions. Kaplan-Meier method was used for the estimation of survival and survival curves were compared with Log-rank test. RESULTS Twenty-five (83.3%) patients had Child-Pugh A and 5 (16.7%) Child-Pugh B, and 24 (80%) patients had BCLC stage B disease and remanining had stage A disease. Lesion size >10 cm was found in 6 patients and 16/7/7 patients had single/two/multiple lesions, respectively. Mean number of TACE was 2.10±1.369. Seventeen (56.7%) patients used sorafenib after TACE whereas 13 (43.3%) patients were followed without any treatment but received consequent TACEs if needed. PFS of all patients was 10 months (range 3-48); it was 13 months for TACE plus sorafenib group and 9 months for TACE group (p=0.081). In subgroup analysis, TACE plus sorafenib group had better PFS (36 vs 12 months) in patients with tumor size > 10 cm (p=0.025). In the analysis of Child- Pugh A cases, PFS of TACE plus sorafenib group was 23 months while it was 10 months in TACE group (p=0.007). CONCLUSION Concurrent treatment in Child-Pugh A group HCC with conventional TACE and sorafenib demonstrates a significant efficacy in patients having tumor size >10 cm. In Child-Pugh A group, PFS was superior in the sorafenib plus TACE group than in TACE alone group.
Collapse
Affiliation(s)
- Gokmen Aktas
- Gaziantep University, School of Medicine, Department of Internal Medicine, Division of Medical Oncology, Gaziantep Oncology Hospital, Gaziantep, Turkey
| | | | | | | | | | | | | |
Collapse
|
3
|
Kus T, Aktas G, Kalender M, Sevinc A, Camci C. P53 and ERCC1 gene polymorphisms can predict the recurence risk of breast cancer. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw364.42] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
4
|
Kalender M, Bulbul F, Aktas G, Kus T, Okyar B, Balakan O, Camci C. Awareness of cancer diagnosis in Turkish patients can increase anxiety and depression: is it true? Ann Oncol 2016. [DOI: 10.1093/annonc/mdw390.72] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
5
|
Suner A, Buyukhatipoglu H, Aktas G, Kus T, Ulasli M, Oztuzcu S, Kalender ME, Sevinc A, Kul S, Camci C. Polymorphisms in the MTHFR gene are associated with recurrence risk in lymph node-positive breast cancer patients. Onco Targets Ther 2016; 9:5603-9. [PMID: 27672331 PMCID: PMC5024764 DOI: 10.2147/ott.s104890] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022] Open
Abstract
Purpose The aim of this study is to clarify the relationship between recurrence risk of breast cancer and methylenetetrahydrofolate reductase (MTHFR) C677T polymorphisms. Patients and methods Breast cancer patients who had undergone surgery in Gaziantep University Oncology Hospital between June 2005 and June 2012 were followed-up and retrospectively enrolled in this study. Blood samples were collected from all patients to assess MTHFR C677T polymorphisms. Stage according to tumor–node–metastasis system, estrogen receptor, progesterone receptor, human epidermal growth factor receptor 2 status, grade of disease, menopausal status, and administered chemotherapy or hormonal therapy were recorded. Effects of these parameters on recurrence risk were evaluated using univariate analysis and multivariate binary logistic regression model. Results Association of MTHFR C677T polymorphisms with recurrence risk was evaluated in 298 patients whose median age was 47 years (range: 21–79 years). In all patients, age (odds ratio [OR] =0.953, P=0.005) and N3 lymph node status (OR =6.293, P=0.001) were found to affect the recurrence risk. While MTHFR homozygote genotype did not have an effect on recurrence risk in all patients, increased risk was observed in lymph node-positive subgroup (OR =4.271; 95% CI 1.515–12.023; P=0.006). Adjusting for age, tumor size (T), and node status (N), MTHFR homozygote genotype had more statistically significant risk for recurrence (OR =3.255; 95% CI 1.047–10.125; P=0.041). Conclusion MTHFR TT genotype was found to be associated with increased recurrence risk in patients with lymph node-positive breast cancer.
Collapse
Affiliation(s)
- Ali Suner
- Division of Medical Oncology, Department of Internal Medicine, Gaziantep Oncology Hospital, University of Gaziantep, Gaziantep, Turkey
| | - Hakan Buyukhatipoglu
- Division of Medical Oncology, Department of Internal Medicine, Gaziantep Oncology Hospital, University of Gaziantep, Gaziantep, Turkey
| | - Gokmen Aktas
- Division of Medical Oncology, Department of Internal Medicine, Gaziantep Oncology Hospital, University of Gaziantep, Gaziantep, Turkey
| | - Tulay Kus
- Division of Medical Oncology, Department of Internal Medicine, Gaziantep Oncology Hospital, University of Gaziantep, Gaziantep, Turkey
| | - Mustafa Ulasli
- Department of Medical Biology, Faculty of Medicine, University of Gaziantep, Gaziantep, Turkey
| | - Serdar Oztuzcu
- Department of Medical Biology, Faculty of Medicine, University of Gaziantep, Gaziantep, Turkey
| | - Mehmet Emin Kalender
- Division of Medical Oncology, Department of Internal Medicine, Gaziantep Oncology Hospital, University of Gaziantep, Gaziantep, Turkey
| | - Alper Sevinc
- Division of Medical Oncology, Department of Internal Medicine, Gaziantep Oncology Hospital, University of Gaziantep, Gaziantep, Turkey
| | - Seval Kul
- Department of Biostatistics, Faculty of Medicine, University of Gaziantep, Gaziantep, Turkey
| | - Celaletdin Camci
- Division of Medical Oncology, Department of Internal Medicine, Gaziantep Oncology Hospital, University of Gaziantep, Gaziantep, Turkey
| |
Collapse
|
6
|
Kus T, Aktas G, Kalender ME, Demiryurek AT, Ulasli M, Oztuzcu S, Sevinc A, Kul S, Camci C. Polymorphism of CYP3A4 and ABCB1 genes increase the risk of neuropathy in breast cancer patients treated with paclitaxel and docetaxel. Onco Targets Ther 2016; 9:5073-80. [PMID: 27574448 PMCID: PMC4990373 DOI: 10.2147/ott.s106574] [Citation(s) in RCA: 33] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022] Open
Abstract
BACKGROUND Interindividual variability of pharmacogenetics may account for unpredictable neurotoxicities of taxanes. METHODS From March 2011 to June 2015, female patients with operable breast cancer who had received docetaxel- or paclitaxel-containing adjuvant chemotherapy were included in this study. All patients were treated with single-agent paclitaxel intravenously (IV) 175 mg/m(2) every 3 weeks for four cycles, or IV 80 mg/m(2) weekly for 12 cycles, and IV 100 mg/m(2) docetaxel for four cycles as adjuvant treatment. We evaluated the relationship between neurotoxicity of taxanes and single-nucleotide polymorphisms of ABCB1, CYP3A4, ERCC1, ERCC2, FGFR4, TP53, ERBB2, and CYP2C8 genes. Taxane-induced neurotoxicity during the treatment was evaluated according to the National Cancer Institute Common Toxicity Criteria version 4.03 prior to each cycle. Chi-squared tests were used to compare the two groups, and multivariate binary logistic regression models were used for determining possible risk factors of neuropathy. RESULTS Pharmacogenetic analysis was performed in 219 females. ABCB1 3435 TT genotype had significantly higher risk for grade ≥2 neurotoxicity (odds ratio [OR]: 2.759, 95% confidence interval [CI]: 1.172-6.493, P: 0.017) compared to TC and CC genotype, and also CYP3A4 392 AA and AG genotype had significantly higher risk for grade ≥2 neurotoxicity (OR: 2.259, 95% CI: 1.033-4.941, P: 0.038) compared to GG genotype. For FDGF4 gene with AG and GG genotype, OR was 1.879 (95% CI: 1.001-3.525, P: 0.048) compared to AA genotype with regard to any grade of neuropathy risk. We could not find any other association of other genotypes with neurotoxicity grades. CONCLUSION ABCB1 3435 TT genotype and CYP3A4 392 AA/AG genotypes may be used as predictors of neurotoxicity during taxane chemotherapy.
Collapse
Affiliation(s)
- Tulay Kus
- Department of Internal Medicine, Division of Medical Oncology, University of Gaziantep, Gaziantep Oncology Hospital, Gaziantep, Turkey
| | - Gokmen Aktas
- Department of Internal Medicine, Division of Medical Oncology, University of Gaziantep, Gaziantep Oncology Hospital, Gaziantep, Turkey
| | - Mehmet Emin Kalender
- Department of Internal Medicine, Division of Medical Oncology, University of Gaziantep, Gaziantep Oncology Hospital, Gaziantep, Turkey
| | | | - Mustafa Ulasli
- Department of Internal Medicine, Division of Medical Oncology, University of Gaziantep, Gaziantep Oncology Hospital, Gaziantep, Turkey
| | - Serdar Oztuzcu
- Department of Medical Biology, Faculty of Medicine, University of Gaziantep, Gaziantep, Turkey
| | - Alper Sevinc
- Department of Internal Medicine, Division of Medical Oncology, University of Gaziantep, Gaziantep Oncology Hospital, Gaziantep, Turkey
| | - Seval Kul
- Department of Biostatistics, Faculty of Medicine, University of Gaziantep, Gaziantep, Turkey
| | - Celaletdin Camci
- Department of Internal Medicine, Division of Medical Oncology, University of Gaziantep, Gaziantep Oncology Hospital, Gaziantep, Turkey
| |
Collapse
|
7
|
Özdemir N, Demirci NS, Yuksel S, Erdem GU, Odabas H, Boruban MC, Hacibekiroglu I, Karaagac M, Ucar M, Ozturk B, Bozkaya Y, Camci C, Zengin N. Clinicopathologic analysis and prognostic factors for survival in early stage patients with ampullary carcinoma. J Clin Oncol 2016. [DOI: 10.1200/jco.2016.34.15_suppl.e15666] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- Nuriye Özdemir
- Yildirim Beyazit University Faculty of Medicine, Department of Medical Oncology, Ankara, Turkey
| | - Nebi Serkan Demirci
- Ankara Numune Education and Research Hospital, Department of medical oncolgy, Ankara, Turkey
| | - Sinemis Yuksel
- Department of Medical Oncology, Dr. Lutfi Kirdar Kartal Education and Research Hospital, Istanbul, Turkey
| | - Gokmen Umut Erdem
- Ankara Numune Education and Research Hospital, Department of medical oncolgy, Ankara, Turkey
| | - Hatice Odabas
- Department of Medical Oncology, Dr. Lutfi Kirdar Kartal Education and Research Hospital, Istanbul, Turkey
| | - Melih Cem Boruban
- Necmettin Erbakan University Meram Medical Faculty Department of Medical Oncology, Konya, Turkey
| | - Ilhan Hacibekiroglu
- Department of Medical Oncology, Trakya University Faculty of Medicine, Edirne, Turkey
| | - Mustafa Karaagac
- Konya Necmeddin Erbakan University, Meram School of Medicine, Diyarbakir, Turkey
| | - Mahmut Ucar
- Erciyes University Faculty of Medicine Department of Medical Oncology, Kayseri, Turkey
| | - Banu Ozturk
- Department of Medical Oncology, Gaziosmanpasa University Faculty of Medicine, Tokat, Turkey
| | - Yakup Bozkaya
- Ankara Numune Education and Research Hospital, Department of medical oncolgy, Ankara, Turkey
| | - Celaletdin Camci
- Department of Medical Oncology, Faculty of Medicine, University of Gaziantep, Gaziantep, Turkey, Gaziantep, Turkey
| | - Nurullah Zengin
- Ankara Numune Education and Research Hospital, Department of medical oncolgy, Ankara, Turkey
| |
Collapse
|
8
|
Igci M, Kalender ME, Borazan E, Bozgeyik I, Bayraktar R, Bozgeyik E, Camci C, Arslan A. High-throughput screening of Sirtuin family of genes in breast cancer. Gene 2016; 586:123-8. [PMID: 27080717 DOI: 10.1016/j.gene.2016.04.023] [Citation(s) in RCA: 36] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/15/2016] [Revised: 03/23/2016] [Accepted: 04/07/2016] [Indexed: 12/13/2022]
Abstract
Mammalian Sirtuins have been shown to perform distinct cellular functions and deregulated expression of these genes was reported to be involved in the development of various malignancies including breast cancer. An increasing number of evidence indicates that Sirtuins have both tumor promoter and tumor suppressor functions. However, the roles of Sirtuins have not been well-reported in breast cancer. In the present study, quantitative expression levels of Sirtuins (SIRT1-7) in breast cancer patients and breast cancer cell lines (MCF-7 and SKBR3) and control cell line (CRL-4010) were assessed by using a high-throughput real-time PCR method. As a result, Sirtuins were found to be differentially expressed in breast cancer tissues and cancer cell lines. Particularly, expressions of SIRT1 and SIRT4 were found to be significantly down-regulated in breast cancer tissues and SKBR3 breast cancer cells. In contrast, SIRT2, SIRT3, and SIRT5 genes were shown to be up-regulated in our study. Although SIRT6 and SIRT7 were also up-regulated in breast cancer tissues, these expression changes were statistically insignificant. Additionally, SIRT2, SIRT3, SIRT5, SIRT6 and SIRT7 were found to be differentially expressed in breast cancer cell lines. Yet, these changes were not well-correlated with tissue expression levels. In conclusion, Sirtuin family of genes shows differential expressions in breast cancer tissues and cells and SIRT1 and SIRT4 seem to play key tumor suppressor roles in breast cancer development. Herein, we report expression levels of Sirtuin family of genes in both breast cancer tissues and cancer cell lines simultaneously.
Collapse
Affiliation(s)
- Mehri Igci
- Gaziantep University, Faculty of Medicine, Department of Medical Biology, Gaziantep, Turkey.
| | - Mehmet Emin Kalender
- Gaziantep University, Faculty of Medicine, Department of Oncology, Gaziantep, Turkey
| | - Ersin Borazan
- Gaziantep University, Faculty of Medicine, Department of General Surgery, Gaziantep, Turkey
| | - Ibrahim Bozgeyik
- Adiyaman University, Faculty of Medicine, Department of Medical Biology, Adiyaman, Turkey
| | - Recep Bayraktar
- Gaziantep University, Faculty of Medicine, Department of Medical Biology, Gaziantep, Turkey
| | - Esra Bozgeyik
- Gaziantep University, Faculty of Medicine, Department of Medical Biology, Gaziantep, Turkey
| | - Celaletdin Camci
- Gaziantep University, Faculty of Medicine, Department of Oncology, Gaziantep, Turkey
| | - Ahmet Arslan
- Gaziantep University, Faculty of Medicine, Department of Medical Biology, Gaziantep, Turkey
| |
Collapse
|
9
|
Aktas G, Kus T, Kalender ME, Sevinc A, Camci C, Kul S. Survival analysis in second-line and third-line chemotherapy with irinotecan followed by topotecan or topotecan followed by irinotecan for extensive-stage small-cell lung cancer patients: a single-center retrospective study. Onco Targets Ther 2016; 9:1921-6. [PMID: 27099522 PMCID: PMC4824370 DOI: 10.2147/ott.s101390] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
Abstract
Purpose The number of patients who make it to receive third-line chemotherapy is increasing owing to the improvements in adverse-event management of chemotherapy for small-cell lung cancer (SCLC). Sequencing of optimal treatment for SCLC is still a challenge for oncologists. In this paper, we aim to present a different approach to the treatment of SCLC. Methods Between January 2008 and July 2014, all patients diagnosed with extensive-stage SCLC and treated with third-line chemotherapy at Gaziantep University Oncology Hospital were analyzed retrospectively. Disease control rates and progression-free survival (PFS) for first-, second-, and third-line chemotherapy, and overall survival (OS) were recorded. Survival analysis was calculated by using Kaplan–Meier method. Results A total of 255 SCLC patients were screened, and 25 of those patients who received third-line chemotherapy were included in this study. Median age was 57±10.131 years (range: 39–74 years). Disease control rates at first-, second-, and third-line chemotherapy were 92%, 68%, and 44%, respectively. Fourteen patients received irinotecan followed by topotecan, and eleven patients received topotecan followed by irinotecan. Second-line median PFS was statistically better in patients treated with irinotecan at second-line compared with those treated with topotecan (21 vs 12 weeks, P=0.018). Comparison of third-line median PFS of the two groups was not statistically significant (14 vs 12 weeks, P=0.986). Median OS was not statistically significant in patients who received irinotecan followed by topotecan vs those who received topotecan followed by irinotecan (18 vs 14 months, P=0.112). Conclusion Sequential monotherapy with topotecan and irinotecan provides a considerable contribution to OS, and second-line irinotecan showed a better PFS, despite a similar OS, compared with topotecan.
Collapse
Affiliation(s)
- Gokmen Aktas
- Division of Medical Oncology, Department of Internal Medicine, School of Medicine, Gaziantep Oncology Hospital, Gaziantep University, Gaziantep, Turkey
| | - Tulay Kus
- Division of Medical Oncology, Department of Internal Medicine, School of Medicine, Gaziantep Oncology Hospital, Gaziantep University, Gaziantep, Turkey
| | - Mehmet Emin Kalender
- Division of Medical Oncology, Department of Internal Medicine, School of Medicine, Gaziantep Oncology Hospital, Gaziantep University, Gaziantep, Turkey
| | - Alper Sevinc
- Division of Medical Oncology, Department of Internal Medicine, School of Medicine, Gaziantep Oncology Hospital, Gaziantep University, Gaziantep, Turkey
| | - Celaletdin Camci
- Division of Medical Oncology, Department of Internal Medicine, School of Medicine, Gaziantep Oncology Hospital, Gaziantep University, Gaziantep, Turkey
| | - Seval Kul
- Department of Biostatistics, School of Medicine, Gaziantep University, Gaziantep, Turkey
| |
Collapse
|
10
|
Kus T, Aktas G, Kalender ME, Sari I, Ulker E, Camci C. Collision tumor consisting of primary follicular lymphoma and adenocarcinoma in the cecum: A case report and literature review. Oncol Lett 2016; 11:2801-2805. [PMID: 27073555 PMCID: PMC4812099 DOI: 10.3892/ol.2016.4310] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/18/2015] [Accepted: 02/04/2016] [Indexed: 12/18/2022] Open
Abstract
The present study reports the case of a collision tumor consisting of follicular lymphoma (FL) and adenocarcinoma in the cecum of a 73-year-old man. To the best of our knowledge, the present study is the 11th case of a collision tumor consisting of colon adenocarcinoma and lymphoma to be reported in the literature, and the first case of cecum adenocarcinoma with low grade FL in the same segment of the cecum and the same regional lymph node to be reported. The present study reviewed the literature to determine treatment options for patients with collision tumors. The present patient was administered with adjuvant chemotherapy for T3N1M0 colon cancer following surgery, due to the dominance of colon adenocarcinoma in the collision tumor. Following the completion of treatment, progression of the untreated FL was observed. In the literature, patients with collision tumors are administered with chemotherapy for stage IV FL, and following the completion of treatment patients have presented with a recurrence of early stage colon adenocarcinoma. The recommended treatment for collision tumors is dependent on the dominant tumor; however, the treatment options for collision tumors in the literature appeared to exacerbate the other tumor. The characteristics of the tumors altered following chemotherapy, and immunological alterations in the tumors due to chemotherapy appear to have contributed to the exacerbation of the tumors. Therefore, patients with early-stage tumors should be considered at risk of recurrence of other malignancies, which are present in collision tumors.
Collapse
Affiliation(s)
- Tulay Kus
- Division of Medical Oncology, Faculty of Medicine, Gaziantep University, Gaziantep, Anatolia 27310, Turkey
| | - Gokmen Aktas
- Division of Medical Oncology, Faculty of Medicine, Gaziantep University, Gaziantep, Anatolia 27310, Turkey
| | - Mehmet Emin Kalender
- Division of Medical Oncology, Faculty of Medicine, Gaziantep University, Gaziantep, Anatolia 27310, Turkey
| | - Ibrahim Sari
- Division of Pathology, Faculty of Medicine, Gaziantep University, Gaziantep, Anatolia 27310, Turkey
| | - Esra Ulker
- Division of Internal Medicine, Faculty of Medicine, Gaziantep University, Gaziantep, Anatolia 27310, Turkey
| | - Celaletdin Camci
- Division of Medical Oncology, Faculty of Medicine, Gaziantep University, Gaziantep, Anatolia 27310, Turkey
| |
Collapse
|
11
|
Kus T, Aktas G, Sevinc A, Oktay C, Kalender ME, Camci C. Tyrosine kinase inhibitors improve parenchymal findings of liver cirrhosis in a patient exhibiting concomitant hepatocellular carcinoma and renal cell cancer. Mol Clin Oncol 2016; 4:290-292. [PMID: 26893877 DOI: 10.3892/mco.2015.677] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/03/2015] [Accepted: 11/03/2015] [Indexed: 12/28/2022] Open
Abstract
Hepatocellular carcinoma (HCC) and renal cell cancer (RCC) are malignancies, which are chemotherapy resistant and fatal at the advanced stages. Previously developed tyrosine kinase inhibitors are used in the treatment of advanced stage disease. In the present case study, a patient using sunitinib for stage IV RCC presented with HCC following 2 years of treatment. A patient who exhibited Child-Pugh class C cirrhosis initially, exhibited a marked improvement of hepatocellular parenchyma findings following treatment with sunitinib. Sunitinib is suggested to have preventive effects on the pathogenesis of liver fibrosis and cirrhosis in vitro, via an anti-vascular endothelial growth factor and anti-platelet-derived growth factor mechanism. However, no clinical supportive study has been performed until now. Improvement of liver functions may be explained in this manner. Therefore, investigations are required with different doses of sunitinib and other tyrosine kinase inhibitors in order to evaluate the efficacy on treatment of cirrhosis progression.
Collapse
Affiliation(s)
- Tulay Kus
- Division of Medical Oncology, Department of Internal Medicine, Gaziantep Oncology Hospital, School of Medicine, Gaziantep University, Gaziantep TR-27310, Turkey
| | - Gokmen Aktas
- Division of Medical Oncology, Department of Internal Medicine, Gaziantep Oncology Hospital, School of Medicine, Gaziantep University, Gaziantep TR-27310, Turkey
| | - Alper Sevinc
- Division of Medical Oncology, Department of Internal Medicine, Gaziantep Oncology Hospital, School of Medicine, Gaziantep University, Gaziantep TR-27310, Turkey
| | - Cemil Oktay
- Department of Radiology, School of Medicine, Akdeniz University, Antalya TR-07100, Turkey
| | - Mehmet Emin Kalender
- Division of Medical Oncology, Department of Internal Medicine, Gaziantep Oncology Hospital, School of Medicine, Gaziantep University, Gaziantep TR-27310, Turkey
| | - Celaletdin Camci
- Division of Medical Oncology, Department of Internal Medicine, Gaziantep Oncology Hospital, School of Medicine, Gaziantep University, Gaziantep TR-27310, Turkey
| |
Collapse
|
12
|
Kalender ME, Cakir M, Ergun S, Oztuzcu S, Cengiz B, Ulasli M, Sevinc A, Camci C. Abstract P6-08-08: Expression and role of ING3 gene in breast cancer. Cancer Res 2016. [DOI: 10.1158/1538-7445.sabcs15-p6-08-08] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Inhibitor of growth (ING) tumor suppressor gene family has been discovered over the past decade and five different genes have been identified from ING1 to ING5. They have some functions like cell transcription regulation, cell cycle control, DNA repair and apoptosis. Because of the fact that ING3 gene expression has not been studied in breast cancer so far, we aimed to determine whether there was a relationship between ING3 gene expression and breast cancer prognostic factors.
Methods: 46 female breast cancer patients in different stages were enrolled to our study. ING3 gene expressions obtained from tumoral and healthy breast tissue samples of patients were evaluated together with pathological and histological parameters.
Results: The median age of the patients was 49 years. ING3 expression rate has been significantly higher in the tumor tissue compared to normal tissue and was statistically significant (p=0.001). In estrogen receptor (ER) and progesterone receptor (PR) positive patients, gene expression ratio was significantly higher than negative ones (p<0.001 and p<0.001, respectively). ING3 expression in tumor tissues of the patients with advanced disease (stage 3-4) was detected higher than ones with early stage disease and it was found to be statistically significant at the border (p=0.048). Moreover, there were no significant changes when ING3 gene expressions were compared with c-erbB2 (Receptor tyrosine-protein kinase erbB-2) status and tumor grade (p> 0.05).
Conclusions: This study was the first study on ING3 gene expression in breast cancer. ING3 gene expression has been shown to be associated with the receptor positivity and advanced stage disease. Further studies should be conducted on the prognostic significance of ING3 gene in breast cancer.
Citation Format: Kalender ME, Cakir M, Ergun S, Oztuzcu S, Cengiz B, Ulasli M, Sevinc A, Camci C. Expression and role of ING3 gene in breast cancer. [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr P6-08-08.
Collapse
Affiliation(s)
- ME Kalender
- Gaziantep University Medical Faculty, Gaziantep, Turkey; Faculty of Medicine, Gaziantep University, Gaziantep, Turkey; Gaziantep University, Gaziantep, Turkey; Gazi University, Ankara, Turkey
| | - M Cakir
- Gaziantep University Medical Faculty, Gaziantep, Turkey; Faculty of Medicine, Gaziantep University, Gaziantep, Turkey; Gaziantep University, Gaziantep, Turkey; Gazi University, Ankara, Turkey
| | - S Ergun
- Gaziantep University Medical Faculty, Gaziantep, Turkey; Faculty of Medicine, Gaziantep University, Gaziantep, Turkey; Gaziantep University, Gaziantep, Turkey; Gazi University, Ankara, Turkey
| | - S Oztuzcu
- Gaziantep University Medical Faculty, Gaziantep, Turkey; Faculty of Medicine, Gaziantep University, Gaziantep, Turkey; Gaziantep University, Gaziantep, Turkey; Gazi University, Ankara, Turkey
| | - B Cengiz
- Gaziantep University Medical Faculty, Gaziantep, Turkey; Faculty of Medicine, Gaziantep University, Gaziantep, Turkey; Gaziantep University, Gaziantep, Turkey; Gazi University, Ankara, Turkey
| | - M Ulasli
- Gaziantep University Medical Faculty, Gaziantep, Turkey; Faculty of Medicine, Gaziantep University, Gaziantep, Turkey; Gaziantep University, Gaziantep, Turkey; Gazi University, Ankara, Turkey
| | - A Sevinc
- Gaziantep University Medical Faculty, Gaziantep, Turkey; Faculty of Medicine, Gaziantep University, Gaziantep, Turkey; Gaziantep University, Gaziantep, Turkey; Gazi University, Ankara, Turkey
| | - C Camci
- Gaziantep University Medical Faculty, Gaziantep, Turkey; Faculty of Medicine, Gaziantep University, Gaziantep, Turkey; Gaziantep University, Gaziantep, Turkey; Gazi University, Ankara, Turkey
| |
Collapse
|
13
|
Kus T, Aktas G, Sevinc A, Kalender ME, Yilmaz M, Kul S, Oztuzcu S, Oktay C, Camci C. Prognostic impact of initial maximum standardized uptake value of (18)F-FDG PET/CT on treatment response in patients with metastatic lung adenocarcinoma treated with erlotinib. Onco Targets Ther 2015; 8:3749-56. [PMID: 26719702 PMCID: PMC4689261 DOI: 10.2147/ott.s94945] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022] Open
Abstract
Purpose To investigate whether the initial maximum standardized uptake value (SUVmax) on fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) has a prognostic significance in metastatic lung adenocarcinoma. Patients and methods Sixty patients (24 females, mean age: 57.9±12 years) with metastatic stage lung adenocarcinoma who used erlotinib and underwent 18F-FDG PET/CT at the time of diagnosis between May 2010 and May 2014 were enrolled in this retrospective study. The patients were stratified according to the median SUVmax value, which was found as 11. Progression-free survival (PFS) rates for 3, 6, and 12 months were examined for SUVmax values and epidermal growth factor receptor (EGFR) mutation status. Results The number of EGFR-sensitizing mutation positive/negative/unknown was 26/17/17, respectively, and the number of patients using erlotinib at first-line, second-line, and third-line therapy was 15, 31, and 14 consecutively. The PFS rates of EGFR mutation positive, negative, and unknown patients for 3 months were 73.1%, 35.3%, and 41.2% (P=0.026, odds ratio [OR]=4.39; 95% confidence interval [CI]: 1.45–13.26), respectively. The PFS rates of EGFR positive, negative, and unknown patients for 6 months were 50%, 29.4%, and 29.4% (P=0.267, OR: 2.4; 95% CI: 0.82–6.96), respectively. The PFS rates of EGFR positive, negative, and unknown patients for 12 months were 42.3%, 29.4%, 23.5% (P=0.408, OR: 2.0; 95% CI: 0.42–5.26), respectively. Thirty-one of 60 patients had SUVmax values ≤11. The PFS rates for 3, 6, and 12 months were 70.5%/28% (P=0.001, OR=9.0; 95% CI: 2.79–29.04), 61.7%/8% (P<0.001, OR=28.35; 95% CI: 5.5–143), and 52.9%/8% (P<0.001, OR=18.69; 95% CI: 3.76–92.9) for low SUVmax (≤11) group/high SUVmax (>11) group, respectively. Conclusion Initial SUVmax value on 18F-FDG PET/CT is found to be a prognostic factor anticipating the response to erlotinib for 3, 6, and 12-month rates of PFS in both EGFR-sensitizing mutation and wild-type tumor group.
Collapse
Affiliation(s)
- Tulay Kus
- Department of Internal Medicine, Division of Medical Oncology, Gaziantep Oncology Hospital, University of Gaziantep, Gaziantep, Turkey
| | - Gokmen Aktas
- Department of Internal Medicine, Division of Medical Oncology, Gaziantep Oncology Hospital, University of Gaziantep, Gaziantep, Turkey
| | - Alper Sevinc
- Department of Internal Medicine, Division of Medical Oncology, Gaziantep Oncology Hospital, University of Gaziantep, Gaziantep, Turkey
| | - Mehmet Emin Kalender
- Department of Internal Medicine, Division of Medical Oncology, Gaziantep Oncology Hospital, University of Gaziantep, Gaziantep, Turkey
| | - Mustafa Yilmaz
- Department of Nuclear Medicine, University of Gaziantep, Gaziantep, Turkey
| | - Seval Kul
- Department of Biostatistics, Faculty of Medicine, University of Gaziantep, Gaziantep, Turkey
| | - Serdar Oztuzcu
- Department of Medical Biology, Faculty of Medicine, University of Gaziantep, Gaziantep, Turkey
| | - Cemil Oktay
- Department of Radiology, Faculty of Medicine, University of Akdeniz, Antalya, Turkey
| | - Celaletdin Camci
- Department of Internal Medicine, Division of Medical Oncology, Gaziantep Oncology Hospital, University of Gaziantep, Gaziantep, Turkey
| |
Collapse
|
14
|
Kus T, Aktas G, Alpak G, Kalender ME, Sevinc A, Kul S, Temizer M, Camci C. Efficacy of venlafaxine for the relief of taxane and oxaliplatin-induced acute neurotoxicity: a single-center retrospective case–control study. Support Care Cancer 2015; 24:2085-2091. [DOI: 10.1007/s00520-015-3009-x] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/11/2015] [Accepted: 11/01/2015] [Indexed: 10/22/2022]
|
15
|
Kalender M, Kuzhan A, Dirier A, Suner A, Camci C. 1544 The impact of smoking on smoking related cancer patients' relatives': Perspective in the Turkish society. Eur J Cancer 2015. [DOI: 10.1016/s0959-8049(16)30634-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
16
|
Sozucan Y, Kalender ME, Sari I, Suner A, Oztuzcu S, Arman K, Yumrutas O, Bozgeyik I, Cengiz B, Igci YZ, Balakan O, Camci C. TRP genes family expression in colorectal cancer. Exp Oncol 2015; 37:208-212. [PMID: 26422106] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/05/2023]
Abstract
UNLABELLED Colorectal cancer (CRC) is the most common cancer of the gastrointestinal tract. Different factors are responsible for the development of CRC. Transient Receptor Potential (TRP) which is an important component of calcium channel is associated with several pathological conditions like cancer, neurodegenerative and cardiovascular diseases. Thirty members of the family of TRP ion channel in mammals have been determined till now. The aim of this study is to investigate TRPM, TRPV and TRPC gene expression levels in tumor tissues of CRC patients and to analyze the relationship of expression in tumor tissue of CRC with other known prognostic factors. MATERIAL AND METHODS In this study, 93 CRC patients were included. The level of TRP gene expression in paraffin blocks of normal and cancerous colorectal tissue samples were studied at the level of mRNA with Real-time PCR. RESULTS The mRNA expression level of TRPV3, TRPV4, TRPV5, TRPM4 and TRPC6 genes in 37 female and 56 male patients diagnosed with CRC was revealed lower in tumor tissue as compared to normal tissue (p < 0.05). No statistically significant differences of mRNA expression levels of other TRP genes were found. CONCLUSIONS TRP gene family like TRPV3, TRPV4, TRPV5, TRPM4 and TRPC6 may be thought as potential genes contributing to tumorigenesis as their expression decreases in CRC as compared to normal tissues.
Collapse
Affiliation(s)
- Y Sozucan
- Department of Medical Oncology, Faculty of Medicine, Gaziantep University, Gaziantep TR-27310, Turkey
| | - M E Kalender
- Department of Medical Oncology, Faculty of Medicine, Gaziantep University, Gaziantep TR-27310, Turkey
| | - I Sari
- Department of Pathology, Faculty of Medicine, Gaziantep University, Gaziantep TR-27310, Turkey
| | - A Suner
- Department of Medical Oncology, Faculty of Medicine, Gaziantep University, Gaziantep TR-27310, Turkey
| | - S Oztuzcu
- Department of Medical Biology, Faculty of Medicine, Gaziantep University, Gaziantep TR-27310, Turkey
| | - K Arman
- Department of Medical Biology, Faculty of Medicine, Gaziantep University, Gaziantep TR-27310, Turkey
| | - O Yumrutas
- Department of Medical Biology, Faculty of Medicine, Adiyaman University, Adiyaman TR-02040, Turkey
| | - I Bozgeyik
- Department of Medical Biology, Faculty of Medicine, Adiyaman University, Adiyaman TR-02040, Turkey
| | - B Cengiz
- Department of Medical Biology, Faculty of Medicine, Gazi University, Ankara TR-06560, Turkey
| | - Y Z Igci
- Department of Medical Biology, Faculty of Medicine, Gaziantep University, Gaziantep TR-27310, Turkey
| | - O Balakan
- Department of Medical Oncology, Faculty of Medicine, Sutcu Imam University, Kahramanmaras, TR-46100, Turkey
| | - C Camci
- Department of Medical Oncology, Faculty of Medicine, Gaziantep University, Gaziantep TR-27310, Turkey
| |
Collapse
|
17
|
Kus T, Aktas G, Kalender ME, Sevinc A, Kul S, Suner A, Ulker E, Camci C. Taxane-induced peripheral sensorial neuropathy in cancer patients is associated with duration of diabetes mellitus: a single-center retrospective study. Support Care Cancer 2015; 24:1175-9. [DOI: 10.1007/s00520-015-2898-z] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/21/2015] [Accepted: 08/09/2015] [Indexed: 12/26/2022]
|
18
|
Alptekin M, Eroglu S, Tutar E, Sencan S, Geyik MA, Ulasli M, Demiryurek AT, Camci C. Gene expressions of TRP channels in glioblastoma multiforme and relation with survival. Tumour Biol 2015; 36:9209-13. [PMID: 26088448 DOI: 10.1007/s13277-015-3577-x] [Citation(s) in RCA: 69] [Impact Index Per Article: 7.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/25/2015] [Accepted: 05/15/2015] [Indexed: 12/14/2022] Open
Abstract
Glioblastoma multiforme (GBM) is one of the most lethal forms of cancer in humans, with a median survival of 10 to 12 months. Glioblastoma is highly malignant since the cells are supported by a great number of blood vessels. Although new treatments have been developed by increasing knowledge of molecular nature of the disease, surgical operation remains the standard of care. The TRP (transient receptor potential) superfamily consists of cation-selective channels that have roles in sensory physiology such as thermo- and osmosensation and in several complex diseases such as cancer, cardiovascular, and neuronal diseases. The aim of this study was to investigate the expression levels of TRP channel genes in patients with glioblastoma multiforme and to evaluate the relationship between TRP gene expressions and survival of the patients. Thirty-three patients diagnosed with glioblastoma were enrolled to the study. The expression levels of 21 TRP genes were quantified by using qRT-PCR with dynamic array 48 × 48 chip (BioMark HD System, Fluidigm, South San Francisco, CA, USA). TRPC1, TRPC6, TRPM2, TRPM3, TRPM7, TRPM8, TRPV1, and TRPV2 were found significantly higher in glioblastoma patients. Moreover, there was a significant relationship between the overexpression of TRP genes and the survival of the patients. These results demonstrate for the first time that TRP channels contribute to the progression and survival of the glioblastoma patients.
Collapse
Affiliation(s)
- M Alptekin
- Department of Neurosurgery, Faculty of Medicine, University of Gaziantep, Gaziantep, 27310, Turkey
| | - S Eroglu
- Department of Medical Biology, Faculty of Medicine, University of Gaziantep, Gaziantep, 27310, Turkey
| | - E Tutar
- Department of Pathology, Faculty of Medicine, University of Gaziantep, Gaziantep, 27310, Turkey
| | - S Sencan
- Department of Medical Biology, Faculty of Medicine, University of Gaziantep, Gaziantep, 27310, Turkey
| | - M A Geyik
- Department of Neurosurgery, Faculty of Medicine, University of Gaziantep, Gaziantep, 27310, Turkey
| | - M Ulasli
- Department of Medical Biology, Faculty of Medicine, University of Gaziantep, Gaziantep, 27310, Turkey
| | - A T Demiryurek
- Department of Pharmacology, Faculty of Medicine, University of Gaziantep, Gaziantep, 27310, Turkey
| | - C Camci
- Department of Medical Oncology, Faculty of Medicine, University of Gaziantep, Gaziantep, 27310, Turkey.
| |
Collapse
|
19
|
Kus T, Aktas G, Sevinc A, Kalender ME, Camci C. Could erlotinib treatment lead to acute cardiovascular events in patients with lung adenocarcinoma after chemotherapy failure? Onco Targets Ther 2015; 8:1341-3. [PMID: 26150726 PMCID: PMC4485179 DOI: 10.2147/ott.s84480] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/22/2023] Open
Abstract
Erlotinib, an epidermal growth factor receptor and tyrosine kinase inhibitor, is a targeted drug that was approved for the treatment of non-small-cell lung cancers and pancreatic cancers. Targeted tyrosine kinase inhibitors are known to have cardiotoxic effects. However, erlotinib does not have a statistically proven effect of increasing acute cardiovascular event (ACE) risk. Preclinical studies showed that beta agonist stimulation among rats that were administered erlotinib led to cardiovascular damage. Thus, there would be an aggregate effect of erlotinib on ACE, although it is not thought to be a cardiotoxic drug itself. In this paper, we present two non-small-cell lung cancer cases that developed ACE under erlotinib treatment.
Collapse
Affiliation(s)
- Tulay Kus
- Department of Internal Medicine, Division of Medical Oncology, Gaziantep University, Gaziantep, Turkey
| | - Gokmen Aktas
- Department of Internal Medicine, Division of Medical Oncology, Gaziantep University, Gaziantep, Turkey
| | - Alper Sevinc
- Department of Internal Medicine, Division of Medical Oncology, Gaziantep University, Gaziantep, Turkey
| | - Mehmet Emin Kalender
- Department of Internal Medicine, Division of Medical Oncology, Gaziantep University, Gaziantep, Turkey
| | - Celaletdin Camci
- Department of Internal Medicine, Division of Medical Oncology, Gaziantep University, Gaziantep, Turkey
| |
Collapse
|
20
|
Ergün S, Camci C, Temiz E, Ulasli M, Kalender ME, Sevinc A, Oztuzcu S. The relationship of miR-122-5p with trastuzumab therapy in breast cancer. J Clin Oncol 2015. [DOI: 10.1200/jco.2015.33.15_suppl.e11593] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- Sercan Ergün
- Department of Medical Biology, Faculty of Medicine, University of Gaziantep, Gaziantep, Turkey, Gaziantep, Turkey
| | - Celaletdin Camci
- Department of Medical Oncology, Faculty of Medicine, University of Gaziantep, Gaziantep, Turkey, Gaziantep, Turkey
| | - Ebru Temiz
- Department of Medical Biology, Faculty of Medicine, University of Gaziantep, Gaziantep, Turkey, Gaziantep, Turkey
| | - Mustafa Ulasli
- Department of Medical Biology, Faculty of Medicine, University of Gaziantep, Gaziantep, Turkey, Gaziantep, Turkey
| | - Mehmet Emin Kalender
- Department of Medical Oncology, Faculty of Medicine, University of Gaziantep, Gaziantep, Turkey, Gaziantep, Turkey
| | - Alper Sevinc
- Gaziantep University Faculty of Medicine, Department of Medical Oncology, Gaziantep, Turkey
| | - Serdar Oztuzcu
- Department of Medical Biology, Faculty of Medicine, University of Gaziantep, Gaziantep, Turkey, Gaziantep, Turkey
| |
Collapse
|
21
|
Kus T, Kalender ME, Aktas G, Suner A, Camci C. Atypical presentation of disseminated intravascular coagulation with synchronous peripheral venous thromboembolism and arterial gangrene in a pancreatic cancer patient: a case report. JOP 2015; 16:195-197. [PMID: 25791556 DOI: 10.6092/1590-8577/2943] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Subscribe] [Scholar Register] [Indexed: 06/04/2023]
Abstract
CONTEXT Cancer is a prothrombotic state and anticancer therapies are often complicated by vascular events. The risk of developing thromboembolic events is substantially increased in patients with pancreatic cancer. One possible presentation of vascular events in pancreatic cancer is disseminated intravascular coagulation (DIC). CASE REPORT In our case a patient with a diagnosis of pancreatic cancer initially presented with thrombosis and received low molecular weight heparin (LMWH) in addition to standard chemotherapy regimen. He was thought to have DIC by assessment of clinical and laboratory findings. CONCLUSION Clinically, thrombosis was first located in the left femoral vein and encountered at right femoral artery after three weeks. This pattern was an unusual presentation of DIC. Subclinical DIC is common in patients presenting with pancreatic cancer and is considered a 'poor' prognostic factor. Acute DIC, on the other hand is a potentially mortal condition.
Collapse
Affiliation(s)
- Tulay Kus
- Division of Oncology, Department of Internal Medicine, University of Gaziantep. Gaziantep, Turkey.
| | | | | | | | | |
Collapse
|
22
|
Kus T, Aktas G, Kalender M, Tutar E, Ulker E, Camci C. Complete response of a recurrent-metastatic liposarcoma with dedifferentiated histological features following the administration of trabectedin and review of literature. J Cancer Res Ther 2015; 11:974-6. [DOI: 10.4103/0973-1482.158032] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
23
|
Camci C, Ergun S, Temiz E, Kirkbes S, Ulasli M, Oztuzcu S. Advancing Apoptosis by MIR-122-5P in Combination with Trastuzumab in SKBR3 Cell Line. Ann Oncol 2014. [DOI: 10.1093/annonc/mdu467.7] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
24
|
Kalender ME, Oztuzcu S, Ulasli M, Suner A, Cengiz B, Ozkara E, Igci YZ, Arslan A, Buyukhatipoglu H, Camci C. Investigation of the Relationship Between Breast Cancer and Transient Receptor Potential (Trp) Genes. Ann Oncol 2014. [DOI: 10.1093/annonc/mdu436.127] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
25
|
Kalender ME, Yildirim IH, Ulasli M, Oztuzcu S, Kizilyer A, Suner A, Balakan O, Tatli AM, Camci C. Micronucleus Score in the Buccal Mucosa of Women with Breast Cancer and the Relationship to Chemotherapy. Ann Oncol 2014. [DOI: 10.1093/annonc/mdu436.21] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
26
|
Balakan O, Kalender ME, Suner A, Cengiz B, Oztuzcu S, Bayraktar R, Borazan E, Babacan T, Camci C. The relationship between urotensin II and its receptor and the clinicopathological parameters of breast cancer. Med Sci Monit 2014; 20:1419-25. [PMID: 25112588 PMCID: PMC4138065 DOI: 10.12659/msm.890459] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023] Open
Abstract
BACKGROUND Urotensin II is a vasoactive polypeptide. It is known that some vasoactive polypeptides are produced and secreted by tumor cells, and act as a paracrine growth stimulant. The aim of this study was to examine the relationship between urotensin II and its receptor's messenger RNA expression in breast cancer. MATERIAL/METHODS Fifty-nine women with breast cancer were included in this study. The median age was 48 years. The relationships between urotensin II and urotensin II receptor mRNA expressions, which were derived from fresh breast cancer tissues and adjacent normal breast tissues, and clinical and pathological parameters, were assessed. RESULTS We found expressions of urotensin II mRNA and its receptor in 55 of 59 breast cancer tissues and in 55 of 59 normal breast tissues. We found a positive significant correlation between urotensin II and its receptor (p=0.001, r=0.632), and found a negative, but insignificant, correlation between urotensin II and age (p=0.038, r=-0.281). Urotensin II levels were higher in the premenopausal group compared to the postmenopausal group (p<0.05). The mean urotensin II receptor expression was higher in the premenopausal group (p<0.05) compared to the postmenopausal group, and its expression was also higher in the group without extra-nodal invasion compared to that of the group with extra-nodal invasion (p=0.001). Urotensin II levels were higher in the group without lymphatic invasion compared to the group with lymphatic invasion (p=0.048). CONCLUSIONS This study is the first in the English medical literature to determine the urotensin II and its receptor mRNA expressions in breast cancer tissues. Consequently, urotensin II seems be associated with menopausal status, and extra-nodal and lymphatic invasion.
Collapse
Affiliation(s)
- Ozan Balakan
- Department of Internal Medicine, Kahramanmaras Sutcu Imam University, Kahramanmaraş, Turkey
| | - Mehmet Emin Kalender
- Department of Medical Oncology, Gaziantep University, School of Medicine, Gaziantep, Turkey
| | - Ali Suner
- Department of Medical Oncology, Gaziantep University, School of Medicine, Gaziantep , Turkey
| | - Beyhan Cengiz
- Department of Physiology, Gaziantep University, School of Medicine, Gaziantep, Turkey
| | - Serdar Oztuzcu
- Department of Medical Biology, Gaziantep University, School of Medicine, Gaziantep, Turkey
| | - Recep Bayraktar
- Department of Medical Biology, Gaziantep University, School of Medicine, Gaziantep, Turkey
| | - Ersin Borazan
- Department of General Surgery, Gaziantep University, School of Medicine, Gaziantep, Turkey
| | - Taner Babacan
- Department of Medical Oncology, Hacettepe University, School of Medicine, Ankara, Turkey
| | - Celaletdin Camci
- Department of Medical Oncology, Gaziantep University, School of Medicine, Gaziantep, Turkey
| |
Collapse
|
27
|
Gogebakan B, Bayraktar R, Suner A, Balakan O, Ulasli M, Izmirli M, Oztuzcu S, Camci C. Do fasudil and Y-27632 affect the level of transient receptor potential (TRP) gene expressions in breast cancer cell lines? Tumour Biol 2014; 35:8033-41. [PMID: 24839003 DOI: 10.1007/s13277-014-1752-0] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/23/2013] [Accepted: 02/13/2014] [Indexed: 12/11/2022] Open
Abstract
Breast cancer (BC) is the most frequent cancer type in women, and the mortality rate is high especially in metastatic disease. Ion channels such as the transient receptor potential (TRP) channels correlate with malignant growth and cancer progression. Hence, some authors have suggested that the expression levels of TRP channels may be used as a marker in the diagnosis and predicting the prognosis of BC. Also, in some recent studies, targeting TRP channels are suggested as a novel treatment strategy in BC. The aim of this study was to investigate the effect of two Rho-kinase (ROCK) inhibitors, fasudil and Y-27632, on the expression levels of TRP channel genes in breast cancer cell lines (ZR-75-1, MCF7, and MDA-MB-231) and breast epithelial cell line (hTERT-HME1). The expression levels of TRP genes were determined by quantitative reverse transcription polymerase chain reaction (qRT-PCR). We found that fasudil had reduced the TRPC1, TRPV2 expression levels in the ZR-75-1, MCF7, and MDA-MB-231 cell lines. On the other hand, fasudil and Y-27632 had reduced TRPM6 expression levels in all cell lines. Y-27632 increased the expression levels of TRPC7 in all cell lines. In conclusion, this is the first study demonstrating that the inhibition of ROCK pathway changes the expression levels of some TRP genes. Also, our study has firstly shown that the expression levels of the TRP genes which are suggested as a diagnostic and prognostic biomarker in BC, were changed with the treatment of fasudil and Y-27632.
Collapse
Affiliation(s)
- Bulent Gogebakan
- Faculty of Medicine, Department of Medical Biology, Mustafa Kemal University, Antakya, Hatay, 31034, Turkey,
| | | | | | | | | | | | | | | |
Collapse
|
28
|
Kalender ME, Sozucan Y, Sari I, Suner A, Oztuzcu S, Bozgeyik I, Cengiz B, Igci YZ, Balakan O, Camci C. TRP genes family expression in colorectal cancer and its relationship with prognostic factors. J Clin Oncol 2014. [DOI: 10.1200/jco.2014.32.3_suppl.513] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
513 Background: Different factors are effective in the development of colorectal cancer (CC). With the discovery of that TRP (transient receptor potential) genes family is an important component of calcium channel, about 30 members of the family of TRP ion channel in mammals have been determined up to the present. TRP channels are associated with many pathological conditions like cancer and cardiovascular diseases as well as the physiological significance of them.. The aim of this study is to investigate TRPM, TRPV and TRPC gene expression levels in tumor tissues of CC patients and to analyze the relationship of expression in tumor tissue of colorectal cancer with other known prognostic factors. Methods: In this study, 93 CC patients whose follow-up and treatment realized in Medical Oncology Department of Gaziantep University Medical Faculty Hospital were analyzed retrospectively. Level of TRP gene expression in paraffin blocks of normal and cancerous colorectal tissue samples of 93 patients were studied at the level of mRNA with real-time PCR. Results: From normal and cancerous colorectal tissues of 37 female and 56 male patients diagnosed with colorectal cancer, expressions of TRPV3, TRPV4, TRPV5, TRPM4, and TRPC6 genes in tumor tissue were detected lower when compared to normal tissue (p < 0.05). When expression levels of other TRP genes in tissues were compared, any significant difference was not found (p > 0.05). There was no meaningful difference between prognostic factors and gene expressions of tumor tissues statistically (p > 0.05). Conclusions: Expression of many proteins in cancer cells compared to normal cells increases or decreases. In CC, TRPV3, TRPV4, TRPV5, TRPM4, and TRPC6 genes of which expression in cancerous tissue decreases may be thought as potential genes contributing to tumorigenesis. To verify this hypothesis, it should be supported with further studies.
Collapse
Affiliation(s)
| | - Yilmaz Sozucan
- Gaziantep University, Medical Faculty, Gaziantep, Turkey
| | - Ibrahim Sari
- Department of Physiology, Gaziantep University, Gaziantep, Turkey
| | - Ali Suner
- Medical Oncology Department, Gaziantep University, Gaziantep, Turkey
| | | | - Ibrahim Bozgeyik
- Department of Medical Biology, Gaziantep University, Gaziantep, Turkey
| | - Beyhan Cengiz
- Department of Physiology, Gaziantep University, Gaziantep, Turkey
| | - Yusuf Z Igci
- Department of Medical Biology, Gaziantep University, Gaziantep, Turkey
| | - Ozan Balakan
- Department of Medical Oncology, Sutcu Imam University, Kahramanmaras, Turkey
| | - Celaletdin Camci
- Department of Medical Oncology, Gaziantep University, Gaziantep, Turkey
| |
Collapse
|
29
|
Buyukhatipoglu H, Balakan O, Suner A, Dirier A, Sevinc A, Bulbul F, Tatli A, Ulas T, Camci C, Kalender M. Depression, anxiety and quality of life through the use of complementary and alternative medicine among breast cancer patients in Turkey. J Cancer Res Ther 2014; 10:962-6. [DOI: 10.4103/0973-1482.138010] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
30
|
Sari I, Berberoglu B, Ozkara E, Oztuzcu S, Camci C, Demiryurek AT. Role of Rho-Kinase Gene Polymorphisms and Protein Expressions in Colorectal Cancer Development. Pathobiology 2013; 80:138-45. [DOI: 10.1159/000341395] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/19/2012] [Accepted: 06/19/2012] [Indexed: 12/15/2022] Open
|
31
|
Oguz E, Alasehirli B, Pehlivan Y, Onat AM, Oztuzcu S, Ozkara E, Kisacik B, Camci C, Demiryürek AT. Association between Rho-kinase (ROCK2) gene polymorphisms and Behçet's disease. Transl Res 2012; 160:428-34. [PMID: 22939913 DOI: 10.1016/j.trsl.2012.08.002] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/29/2012] [Revised: 08/07/2012] [Accepted: 08/09/2012] [Indexed: 12/14/2022]
Abstract
Behçet's disease (BD) is a multi-systemic vasculitis. The aim of this study was to investigate the association between Rho-kinase (ROCK2) gene polymorphisms and patients with BD in a Turkish population. A total of 194 BD patients and 276 healthy controls with similar age and sex were included to this study. Polymorphisms were analyzed in genomic DNA using a BioMark 96.96 dynamic array system. mRNA from blood samples was extracted, and real-time polymerase chain reaction was performed for ROCK2 gene expression. There were marked changes in both genotype (TT, 41.8%; TA, 30.3%) and allele (T, 57%; A, 43%) frequencies for the rs35768389 (Asp601Val) polymorphism in patients compared with controls (TT, 64.6%; TA, 9.4%, P < 0.0001; T, 69.3%; A, 30.7%, P = 0.0004). Although CC genotype (52.0%) of rs1515219 polymorphism were more frequent, CT genotype (27.7%) were less frequent among the patients than controls (CC, 31.7%, CT, 44.6%, P = 0.0001). There was an increase in C allele (65.8% vs 54.0%) and decrease in T allele frequencies (34.2% vs 46.0%, P = 0.001) in patients. However, no associations were found with rs726843, rs2290156, rs965665, rs10178332, rs2230774, rs6755196, rs10929732, and rs34945852 polymorphisms. There was an increase in peripheral blood mRNA ROCK2 expressions in patients. This is the first study to examine the involvement of ROCK2 gene variation in the risk of incident BD. The results strongly suggest that ROCK2 gene polymorphisms may modify individual susceptibility to BD in the Turkish population.
Collapse
Affiliation(s)
- Elif Oguz
- Department of Medical Pharmacology, University of Gaziantep, Gaziantep, Turkey
| | | | | | | | | | | | | | | | | |
Collapse
|
32
|
Igci M, Cakmak EA, Oztuzcu S, Bayram A, Arslan A, Gogebakan B, Igci YZ, Cengiz B, Ozkara E, Camci C, Demiryurek AT. Mutational screening of the SOCS3 gene promoter in metastatic colorectal cancer patients. Genet Test Mol Biomarkers 2012; 16:1395-400. [PMID: 23046072 DOI: 10.1089/gtmb.2012.0208] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/29/2023] Open
Abstract
Cytokine-induced expression of suppressors of cytokine signalling (SOCS) molecules is important for the negative feedback control of STAT-dependent cytokine signalling. The aim of this study was to investigate possible association between the promoter region polymorphisms of the SOCS3 gene and metastatic colorectal carcinoma in a Turkish population. The DNA samples obtained from 103 patients and 109 healthy individuals were analyzed by polymerase chain reaction/single-strand conformation polymorphism (SSCP), and nucleotide sequence analysis. Five sets of primers designed for the SOCS3 gene were used, and we did not detect significant differences in genotype frequencies for any of these polymorphisms between the study groups. Only the S3P1 region showed polymorphism and displayed three (1,2,4, 2,3,4 and 2,4) genotypes. Interestingly, 2,3,4 genotype was observed in 3 patients, but not in controls. Moreover, the sequence analysis revealed that the nucleotides positioned at -914 and -1031 nt had the polymorphisms. Nucleotide sequence analysis of SSCP band 1 and band 3 revealed C-914A (rs12953258) and T-1031C (rs111033850) polymorphisms, respectively. The T-1031C polymorphism lies in the border of the STAT-binding site. The T-1031C polymorphism (rs111033850) is a newly identified single nucleotide polymorphism with this study, and we submitted this to the NCBI database. However, these results suggested that there is no marked association between SOCS3 gene promoter region polymorphisms and the risk of developing metastatic colorectal cancer.
Collapse
Affiliation(s)
- Mehri Igci
- Department of Medical Biology, Gaziantep University, Gaziantep, Turkey.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
33
|
Akbulut H, Altundag MK, Saip P, Coskun HS, Camci C, Ozkan M, Paydas S, Zengin N, Alco G, Aliustaoglu M, Basaran G, Yamac D, Yucel I, Goker E, Yaman E, Isikdogan A, Ozisik YY, Topuz E, Ozdogan M, Icli F. The changing pattern of risk factors and disease characteristics of breast cancer in Turkey: A cross-sectional study of a Turkish oncology group (BREASTTURK). J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.e12007] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
34
|
Yalcin S, Uslu R, Dane F, Yilmaz U, Zengin N, Buyukunal E, Buyukberber S, Camci C, Sencan O, Kilickap S. Bevacizumab plus capecitabine as maintenance treatment after initial treatment with bevacizumab plus XELOX in previously untreated metastatic colorectal cancer: Updated findings from a randomized, multicenter phase III trial. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.3579] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
35
|
Yalcin S, Uslu R, Dane F, Yilmaz U, Zengin N, Buyukunal E, Buyukberber S, Camci C, Sencan O, Kilickap S. A randomized, multicenter phase III trial of bevacizumab plus capecitabine as maintenance treatment after initial treatment with bevacizumab plus XELOX in previously untreated metastatic colorectal cancer. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.4_suppl.474] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
474 Background: Colorectal cancer is one of the most frequent malignancies, second to breast cancer in women and third to lung cancer and prostate cancer in men. The aim of this study in first-line metastatic colorectal cancer (mCRC) was to achieve a better progression-free survival (PFS) and less risk of toxicity by administrating bevacizumab (BEV) + capecitabine + oxaliplatin (XELOX) for 6 cycles, stop oxaliplatin and go with maintenance therapy (BEV + capecitabine) until progression. Methods: BEV (7.5 mg/kg) + XELOX (capecitabine 1,000 mg/m2 bid d1–14 + oxaliplatin 130 mg/m2 d1 q3w) were administered until progression (Arm A) or 6 cycles of BEV + XELOX followed by BEV + capecitabine were administered until progression (Arm B). PFS was the primary endpoint; secondary endpoints included overall survival (OS), objective response rate (ORR), and safety. A sample size of 118 patients (pts) was calculated to achieve 80% power to detect an increase of 1.5 months in median PFS between Arm A (9.5 months) and Arm B (11.0 months) with a standard deviation of 3.9 months and significance level of 0.05 using a 10% drop-out rate. Results: A total of 122 pts were randomized. No significant differences were found in demographic characteristics between the two arms. Median treatment period was 6.1 (range 0.7–13.4) and 6.8 (range 0.7–12.4) months in Arms A and B, respectively. Interim analysis showed no statistically significant differences in median PFS and ORR between arms (see table). Tolerability was also acceptable in both arms with grade 3/4 diarrhoea in 7.7% vs. 8.2%, weakness in 15.2% vs. 8.4%, hand-foot syndrome in 6.3% vs. 9.4%, and neuropathy in 2.8% vs. 4.6% of pts in Arms A and B, respectively. Conclusions: BEV + capecitabine as maintenance therapy following induction BEV + XELOX is non-inferior to continuous BEV + XELOX until progression. While this study is ongoing, these interim findings suggest that maintenance therapy with BEV + capecitabine is an appropriate option following induction BEV + XELOX in pts with mCRC. [Table: see text] [Table: see text]
Collapse
Affiliation(s)
- S. Yalcin
- Hacettepe University Hospital, Ankara, Turkey; Ege University Hospital, Izmir, Turkey; Marmara University Hospital, Istanbul, Turkey; Dokuz Eylul University Hospital, Izmir, Turkey; Ankara Numune Research Hospital, Ankara, Turkey; Istanbul University Cerrahpasa Medical Faculty Hospital, Istanbul, Turkey; Gazi University Hospital, Ankara, Turkey; Gaziantep University Hospital, Gaziantep, Turkey; Ankara University Hospital, Ankara, Turkey
| | - R. Uslu
- Hacettepe University Hospital, Ankara, Turkey; Ege University Hospital, Izmir, Turkey; Marmara University Hospital, Istanbul, Turkey; Dokuz Eylul University Hospital, Izmir, Turkey; Ankara Numune Research Hospital, Ankara, Turkey; Istanbul University Cerrahpasa Medical Faculty Hospital, Istanbul, Turkey; Gazi University Hospital, Ankara, Turkey; Gaziantep University Hospital, Gaziantep, Turkey; Ankara University Hospital, Ankara, Turkey
| | - F. Dane
- Hacettepe University Hospital, Ankara, Turkey; Ege University Hospital, Izmir, Turkey; Marmara University Hospital, Istanbul, Turkey; Dokuz Eylul University Hospital, Izmir, Turkey; Ankara Numune Research Hospital, Ankara, Turkey; Istanbul University Cerrahpasa Medical Faculty Hospital, Istanbul, Turkey; Gazi University Hospital, Ankara, Turkey; Gaziantep University Hospital, Gaziantep, Turkey; Ankara University Hospital, Ankara, Turkey
| | - U. Yilmaz
- Hacettepe University Hospital, Ankara, Turkey; Ege University Hospital, Izmir, Turkey; Marmara University Hospital, Istanbul, Turkey; Dokuz Eylul University Hospital, Izmir, Turkey; Ankara Numune Research Hospital, Ankara, Turkey; Istanbul University Cerrahpasa Medical Faculty Hospital, Istanbul, Turkey; Gazi University Hospital, Ankara, Turkey; Gaziantep University Hospital, Gaziantep, Turkey; Ankara University Hospital, Ankara, Turkey
| | - N. Zengin
- Hacettepe University Hospital, Ankara, Turkey; Ege University Hospital, Izmir, Turkey; Marmara University Hospital, Istanbul, Turkey; Dokuz Eylul University Hospital, Izmir, Turkey; Ankara Numune Research Hospital, Ankara, Turkey; Istanbul University Cerrahpasa Medical Faculty Hospital, Istanbul, Turkey; Gazi University Hospital, Ankara, Turkey; Gaziantep University Hospital, Gaziantep, Turkey; Ankara University Hospital, Ankara, Turkey
| | - E. Buyukunal
- Hacettepe University Hospital, Ankara, Turkey; Ege University Hospital, Izmir, Turkey; Marmara University Hospital, Istanbul, Turkey; Dokuz Eylul University Hospital, Izmir, Turkey; Ankara Numune Research Hospital, Ankara, Turkey; Istanbul University Cerrahpasa Medical Faculty Hospital, Istanbul, Turkey; Gazi University Hospital, Ankara, Turkey; Gaziantep University Hospital, Gaziantep, Turkey; Ankara University Hospital, Ankara, Turkey
| | - S. Buyukberber
- Hacettepe University Hospital, Ankara, Turkey; Ege University Hospital, Izmir, Turkey; Marmara University Hospital, Istanbul, Turkey; Dokuz Eylul University Hospital, Izmir, Turkey; Ankara Numune Research Hospital, Ankara, Turkey; Istanbul University Cerrahpasa Medical Faculty Hospital, Istanbul, Turkey; Gazi University Hospital, Ankara, Turkey; Gaziantep University Hospital, Gaziantep, Turkey; Ankara University Hospital, Ankara, Turkey
| | - C. Camci
- Hacettepe University Hospital, Ankara, Turkey; Ege University Hospital, Izmir, Turkey; Marmara University Hospital, Istanbul, Turkey; Dokuz Eylul University Hospital, Izmir, Turkey; Ankara Numune Research Hospital, Ankara, Turkey; Istanbul University Cerrahpasa Medical Faculty Hospital, Istanbul, Turkey; Gazi University Hospital, Ankara, Turkey; Gaziantep University Hospital, Gaziantep, Turkey; Ankara University Hospital, Ankara, Turkey
| | - O. Sencan
- Hacettepe University Hospital, Ankara, Turkey; Ege University Hospital, Izmir, Turkey; Marmara University Hospital, Istanbul, Turkey; Dokuz Eylul University Hospital, Izmir, Turkey; Ankara Numune Research Hospital, Ankara, Turkey; Istanbul University Cerrahpasa Medical Faculty Hospital, Istanbul, Turkey; Gazi University Hospital, Ankara, Turkey; Gaziantep University Hospital, Gaziantep, Turkey; Ankara University Hospital, Ankara, Turkey
| | - S. Kilickap
- Hacettepe University Hospital, Ankara, Turkey; Ege University Hospital, Izmir, Turkey; Marmara University Hospital, Istanbul, Turkey; Dokuz Eylul University Hospital, Izmir, Turkey; Ankara Numune Research Hospital, Ankara, Turkey; Istanbul University Cerrahpasa Medical Faculty Hospital, Istanbul, Turkey; Gazi University Hospital, Ankara, Turkey; Gaziantep University Hospital, Gaziantep, Turkey; Ankara University Hospital, Ankara, Turkey
| |
Collapse
|
36
|
Aykan N, Demir G, Disci R, Yalcin S, Turhal NS, Ozdogan M, Ozkan M, Yaren A, Camci C, Akbulut H. Profile of the colorectal (CRC) cancer (Ca) patients (PTS) in Turkey: A cross-sectional disease registry study—A Turkish Oncology Group trial. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.4_suppl.394] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
394 Background: CRC Ca is one of the most common Ca worldwide. This study was designed to determine the profile of recently diagnosed CRC Ca pts in Turkey. Methods: In this national, multicenter cross-sectional disease registry study, data for 968 pts diagnosed CRC Ca were analyzed. This non-interventional study was supported by sanofi-aventis. Results: From October 2008 to October 2009, 662 colon (68%), 306 rectum (32%) Ca pts were registered from 21 centers in 7 geographic regions of Turkey. Characteristics are as follows. Male 61%, mean age was 60±12 for colon and 57±13 for rectum Ca. The ratio of colon and rectum Ca were equal in the Black Sea region, colon Ca was higher in the other 5 regions except Eastern Anatolia where the highest percentage of rectum Ca was observed (55% vs 45%). Red meat consumption was significantly high only in Eastern Anatolia (p<0.001). The consumption of alcohol, fruit and vegetables didn't show any difference. The percentage of smoking was slightly higher in the rectum Ca group (21% vs 16%, NS). The CRC family history was a risk factor in 7.4% colon, and in 5.6% rectum Ca pts. Among all pts, 1.5% had familial poliposis and only 0.4% had Lynch syndrome. Hypertension (29%) and diabetes mellitus (15%) were the most frequent concomitant diseases. Mean body mass index was 26 ± 4 in colon and 26 ± 5 in rectum Ca pts. Median time between the onset of symptoms and diagnosis was 3 months (mo) for colon and 4 mo for rectum Ca pts. For 46% of pts this time was longer than 4 mo. The mean weight loss in last 6 mo was slightly higher in colon Ca pts (3.9 vs 3.4 kg). Anemia was more frequent in colon Ca pts (p<0.05). Primary tumor location: sigmoid 37% for colon Ca, distal rectum 61% for rectum Ca. In total, 86% of pts were operated (88% of colon, 80% of rectum Ca). In 26% of pts emergency surgery was performed. AJCC staging at diagnosis: I-7%, II-26%, III-35%, IV-32% in colon and I-14%, II-22%, III-39%, IV:25% in rectum. Conclusions: This study showed that colon Ca was more frequent and most of the cases were operated. Data also revealed that pts were diagnosed at considerably later stages. The role of the consumption of red meat, obesity and smoking should be evaluated in larger trial in the future. [Table: see text]
Collapse
Affiliation(s)
- N. Aykan
- University of Istanbul, Istanbul, Turkey; Medical Oncology Department, Istanbul Bilim University School of Medicine, Istanbul, Turkey; Istanbul University Institute of Oncology, Istanbul, Turkey; Hacettepe University, Ankara, Turkey; Medical Oncology Department, Marmara University Hospital, Istanbul, Turkey; Department of Medical Oncology, Akdeniz University, Antalya, Turkey; Department of Medical Oncology, Erciyes University Medical Faculty, Kayseri, Turkey; Pamukkale University Denizli, Istanbul,
| | - G. Demir
- University of Istanbul, Istanbul, Turkey; Medical Oncology Department, Istanbul Bilim University School of Medicine, Istanbul, Turkey; Istanbul University Institute of Oncology, Istanbul, Turkey; Hacettepe University, Ankara, Turkey; Medical Oncology Department, Marmara University Hospital, Istanbul, Turkey; Department of Medical Oncology, Akdeniz University, Antalya, Turkey; Department of Medical Oncology, Erciyes University Medical Faculty, Kayseri, Turkey; Pamukkale University Denizli, Istanbul,
| | - R. Disci
- University of Istanbul, Istanbul, Turkey; Medical Oncology Department, Istanbul Bilim University School of Medicine, Istanbul, Turkey; Istanbul University Institute of Oncology, Istanbul, Turkey; Hacettepe University, Ankara, Turkey; Medical Oncology Department, Marmara University Hospital, Istanbul, Turkey; Department of Medical Oncology, Akdeniz University, Antalya, Turkey; Department of Medical Oncology, Erciyes University Medical Faculty, Kayseri, Turkey; Pamukkale University Denizli, Istanbul,
| | - S. Yalcin
- University of Istanbul, Istanbul, Turkey; Medical Oncology Department, Istanbul Bilim University School of Medicine, Istanbul, Turkey; Istanbul University Institute of Oncology, Istanbul, Turkey; Hacettepe University, Ankara, Turkey; Medical Oncology Department, Marmara University Hospital, Istanbul, Turkey; Department of Medical Oncology, Akdeniz University, Antalya, Turkey; Department of Medical Oncology, Erciyes University Medical Faculty, Kayseri, Turkey; Pamukkale University Denizli, Istanbul,
| | - N. S. Turhal
- University of Istanbul, Istanbul, Turkey; Medical Oncology Department, Istanbul Bilim University School of Medicine, Istanbul, Turkey; Istanbul University Institute of Oncology, Istanbul, Turkey; Hacettepe University, Ankara, Turkey; Medical Oncology Department, Marmara University Hospital, Istanbul, Turkey; Department of Medical Oncology, Akdeniz University, Antalya, Turkey; Department of Medical Oncology, Erciyes University Medical Faculty, Kayseri, Turkey; Pamukkale University Denizli, Istanbul,
| | - M. Ozdogan
- University of Istanbul, Istanbul, Turkey; Medical Oncology Department, Istanbul Bilim University School of Medicine, Istanbul, Turkey; Istanbul University Institute of Oncology, Istanbul, Turkey; Hacettepe University, Ankara, Turkey; Medical Oncology Department, Marmara University Hospital, Istanbul, Turkey; Department of Medical Oncology, Akdeniz University, Antalya, Turkey; Department of Medical Oncology, Erciyes University Medical Faculty, Kayseri, Turkey; Pamukkale University Denizli, Istanbul,
| | - M. Ozkan
- University of Istanbul, Istanbul, Turkey; Medical Oncology Department, Istanbul Bilim University School of Medicine, Istanbul, Turkey; Istanbul University Institute of Oncology, Istanbul, Turkey; Hacettepe University, Ankara, Turkey; Medical Oncology Department, Marmara University Hospital, Istanbul, Turkey; Department of Medical Oncology, Akdeniz University, Antalya, Turkey; Department of Medical Oncology, Erciyes University Medical Faculty, Kayseri, Turkey; Pamukkale University Denizli, Istanbul,
| | - A. Yaren
- University of Istanbul, Istanbul, Turkey; Medical Oncology Department, Istanbul Bilim University School of Medicine, Istanbul, Turkey; Istanbul University Institute of Oncology, Istanbul, Turkey; Hacettepe University, Ankara, Turkey; Medical Oncology Department, Marmara University Hospital, Istanbul, Turkey; Department of Medical Oncology, Akdeniz University, Antalya, Turkey; Department of Medical Oncology, Erciyes University Medical Faculty, Kayseri, Turkey; Pamukkale University Denizli, Istanbul,
| | - C. Camci
- University of Istanbul, Istanbul, Turkey; Medical Oncology Department, Istanbul Bilim University School of Medicine, Istanbul, Turkey; Istanbul University Institute of Oncology, Istanbul, Turkey; Hacettepe University, Ankara, Turkey; Medical Oncology Department, Marmara University Hospital, Istanbul, Turkey; Department of Medical Oncology, Akdeniz University, Antalya, Turkey; Department of Medical Oncology, Erciyes University Medical Faculty, Kayseri, Turkey; Pamukkale University Denizli, Istanbul,
| | - H. Akbulut
- University of Istanbul, Istanbul, Turkey; Medical Oncology Department, Istanbul Bilim University School of Medicine, Istanbul, Turkey; Istanbul University Institute of Oncology, Istanbul, Turkey; Hacettepe University, Ankara, Turkey; Medical Oncology Department, Marmara University Hospital, Istanbul, Turkey; Department of Medical Oncology, Akdeniz University, Antalya, Turkey; Department of Medical Oncology, Erciyes University Medical Faculty, Kayseri, Turkey; Pamukkale University Denizli, Istanbul,
| | | |
Collapse
|
37
|
Camci C, Firoiu E, Gumus M, Hurtado de Mendoza F, Chavez-Zamudio MA, Davidson N, Brychta M, Donadio M, Soldatenkova V, Benhadji KA. Factors associated with the choice of taxane monotherapy or combination in the management of advanced breast cancer: Results of an international observational study. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.1132] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
38
|
Kalender M, Demiryürek S, Oztuzcu S, Kizilyer A, Demiryürek A, Sevinc A, Dikilitas M, Yildiz R, Camci C. Association between the Thr431asn Polymorphism of the Rock2 Gene and Breast Cancer. Cancer Res 2009. [DOI: 10.1158/0008-5472.sabcs-09-3038] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: The objective of this study was to analyze the genotype distributions and allele frequencies for Threonine431Asparagine (Thr431Asn) and Arginine83Lysine (Arg83Lys) polymorphisms of the Rho kinase2 (ROCK2) gene among the breast cancer patients.Material and Methods: In this case-control study, 223 patients with breast cancer were recruited and divided into two groups according to metastases (n=128) and without metastases (n=95). Genomic DNA from the patients and the control cases (n=150) was analyzed by real-time PCR using a Light-Cycler.Results: Neither genotype distributions nor the allele frequencies for the Arg83Lys polymorphism showed a significant difference between the groups. Although no marked changes was observed with no metastasis group, a statistically significant association was found between the control and metastatic group for the Thr431Asn polymorphism of the ROCK2 gene. Further analysis revealed that there were marked associations of this polymorphism with bone, liver, and lung metastases. Homozygous carriers of the Thr431Thr genotype were more frequent among the metastatic patients (39.8%) than among controls (26.0%; P =0.0485). There was also an increase in Thr431 allele (60.5% in patients vs 51.7% in controls) and decrease in Asn431 allele frequencies (48.3% in control vs 39.5% in patients) in metastatic groups (P =0.0356). Progesterone and estrogen receptor negativity was more frequent among metastatic patients carrying a Thr431 allele when compared to the nonmetastatic group.Discussion: Our resulsts are the first to demonstrate that Thr431Asn polymorphism of the ROCK2 gene could be a risk factor for the metastases of the breast cancer, and may help in predicting the prognosis.
Citation Information: Cancer Res 2009;69(24 Suppl):Abstract nr 3038.
Collapse
Affiliation(s)
- M. Kalender
- 1Gaziantep University Medical Faculty, Gaziantep Oncology Hospital, Turkey
| | - S. Demiryürek
- 2Gaziantep University, Medical Faculty, Gaziantep School of Health, Turkey
| | - S. Oztuzcu
- 3Gaziantep University, Medical Faculty, Turkey
| | - A. Kizilyer
- 4Gaziantep University, Medical Faculty, Turkey
| | | | - A. Sevinc
- 6Gaziantep University, Medical Faculty, Gaziantep Oncology Hospital, Turkey
| | - M. Dikilitas
- 7Erciyes University, Faculty of Medicine, Turkey
| | - R. Yildiz
- 8Gazi University, Faculty of Medicine, Turkey
| | - C. Camci
- 9Gaziantep University, Medical Faculty, Gaziantep Oncology Hospital, Turkey
| |
Collapse
|
39
|
Kalender ME, Dirier A, Sevinc A, Camci C. Depression-anxiety and quality of life and the use of complementary and alternative medicine among breast cancer patients in Turkey. Cancer Res 2009. [DOI: 10.1158/0008-5472.sabcs-3130] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Abstract #3130
Purpose: Breast cancer is the most common cancer type among women. The aim of this study was to examine the association between the use of complementary and alternative medicine (CAM) and quality of life, and anxiety and depression, and demographic characteristics of Anatolian women with breast cancer.
 Methods: Quality of life was measured with European Organization for Treatment and Research of Cancer (EORTC) quality of life core questionnaire (QLQ-C30, version 3.0) and anxiety and depression was measured with Hospital Anxiety and Depression Scale (HADS). The demographic characteristics of patients were filled by patient to a standard form.
 Results: Totally 122 patients with breast cancer were enrolled, and 50% (n=61) of patients reported that they were using CAM. The most commonly used CAM methods were stinging nettle (57%) and prayer and spiritual healing (49%). The statistical analysis showed that, there was a meaningful correlation between CAM usage and education level (p=0.031) and radiotherapy (p=0.002). There was no relationship between use of CAM and patients age, time since diagnosis, stage of cancer, chemotherapy using, smoking and residence. Analysis of patients showed a positive correlation between CAM and RF2 (Role Functioning) (p=0.014) and FI (Financial Difficulties) (p=0.011) and negative correlation between CAM and EF (Emotional Functioning) (p=0.033). There was no correlation between use of CAM and anxiety and depression scale. The RF2 (p=0.02), EF (p=0.047), FA (Fatigue) (p=0.038), PA (Pain) (p=0.043) and depression results (p=0.008) were better at patients with high education level. We analysed CAM using in patients living in rural or urban area, and the EF (p=0.006), CF (Cognitive Functioning) (p=0.027), PA (p=0.025), DY (Dyspnoea) (p=0.045) and DI (Diarrhoea) (p=0.000) results were better in urban area.
 Conclusions: According to the various studies in the literature, 20-83.3% of breast cancer patients were using CAM and the CAM methods are different in different countries and cultures. Our results suggest that the use of CAM among Anatolian women with breast cancer is popular. This study findings showed no correlation between anxiety and depression and CAM usage. There is a tendency to CAM usage in patients with financial problems. Emotional functioning was also worse in those patients. The study results showed that the use of CAM is more common among breast patients with bad emotional status and poor financial status.
Citation Information: Cancer Res 2009;69(2 Suppl):Abstract nr 3130.
Collapse
Affiliation(s)
- ME Kalender
- 1 Gaziantep University Medicine School, Medical Oncology, Gaziantep, Turkey
| | - A Dirier
- 2 Gaziantep University Medicine School, Radiation Oncology, Gaziantep, Turkey
| | - A Sevinc
- 1 Gaziantep University Medicine School, Medical Oncology, Gaziantep, Turkey
| | - C Camci
- 1 Gaziantep University Medicine School, Medical Oncology, Gaziantep, Turkey
| |
Collapse
|
40
|
Sevinc A, Camci C, Sari I, Kalender ME, Er O, Soyuer I, Dikilitas M, Yılmaz U, Sagol O, Alacacioglu A. Cyclooxygenase-2 expression in gastrointestinal stromal tumours. J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.15643] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
41
|
Buyukberber S, Sari I, Camci C, Buyukberber NM, Sevinc A, Turk HM. Adrenomedullin expression does not correlate with survival in lung cancer. Med Oncol 2007; 24:245-9. [PMID: 17848751 DOI: 10.1007/bf02698047] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/17/2006] [Revised: 11/30/1999] [Accepted: 12/16/2006] [Indexed: 11/27/2022]
Abstract
It is suggested that adrenomedullin (AM) plays a role in lung carcinogenesis although, to confirm this suggestion, further clinical studies are needed to determine its relationship with prognosis in lung cancer. Archived 50 paraffin-embedded tumor samples of the lung were retrospectively evaluated for AM expression by immunohistochemistry and analyzed for a possible correlation with patient characteristics and survival. Quantitation of immunoreactivity was accomplished using an immunohistochemical scoring system. The pulmonary resection specimens contained 22 squamous cell carcinomas, 15 adenocarcinomas, and 13 small cell carcinomas. Non-small cell carcinomas of the lung were more likely to express AM than small cell carcinomas of the lung. Ninety-one percent of squamous cell carcinomas and 87% of adenocarcinomas expressed AM at a moderate to strong level and grade2-4 (30-100%), which were significantly higher from the non-neo-plastic lung tissue. Twenty-three percent of small cell carcinomas of lung expressed AM. Interestingly, AM immunoreactivity was essentially weak and grade 1 (<%30) in this group. AM expression is upregulated in non-small cell carcinomas of the lung, whereas it is downregulated in small cell carcinomas and non-neo-plastic lung tissues. AM expression did not show any correlation with the differentiation of the tumor, the stage of cancer, and the overall survival of patients. These results did not support the role of adrenomedullin as an independent survival factor for lung cancer. However, AM inhibition in conjunction with other anti-angiogenic agents may be useful in the prevention and treatment of malignancies.
Collapse
Affiliation(s)
- S Buyukberber
- Department of Medical Oncology, Gazi University, Medical Faculty, Gazi Hospital, Ankara, 06500.
| | | | | | | | | | | |
Collapse
|
42
|
Rizvi S, Camci C, Yong Y, Parker G, Shrago S, Stokes K, Wright H, Sebastian A, Gurakar A. Is post-Lipiodol CT better than i.v. contrast CT scan for early detection of HCC? A single liver transplant center experience. Transplant Proc 2007; 38:2993-5. [PMID: 17112883 DOI: 10.1016/j.transproceed.2006.08.125] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/30/2006] [Indexed: 11/29/2022]
Abstract
Hepatocellular carcinoma is a highly vascular neoplasm usually arising from a cirrhotic liver. Delayed, noncontrast, computed tomography (CT) imaging after 7 to 14 days reveals an oil-based contrast agent to be concentrated in the tumor but not in normal hepatic parenchyma. The aim of this study was to retrospectively correlate the post Lipiodol CT scan findings with respect to tumor size in the explanted liver. We retrospectively reviewed adult patients who had undergone orthotopic liver transplantation between November 1995 and December 2004 and also had an hepatic arteriogram with Lipiodol injection as part of their pretransplant workup. We calculated sensitivity, specificity, false-negativity, false-positivity, and accuracy of the test, as well as positive and negative predictive values. Lipiodol CT exam had sensitivity of 1.0; specificity of 0.6 with a calculated positive predictive value of 0.89 and a negative predictive value of 1.0. Overall accuracy of Lipiodol CT scan test was found to be 0.91, which was superior to an intravenous contrast CT alone. In conclusion, because of the higher sensitivity and accuracy values, hepatic arterial Lipiodol injection can be considered during the pretransplantation workup of high-risk cirrhotic patients, since the current model for End-stage Liver Disease scoring system for hepatocellular carcinoma is built on the ultimate bulk of the tumor. Further multicenter, controlled, large-volume prospective studies are warranted to verify this observation.
Collapse
Affiliation(s)
- S Rizvi
- Section of Gastroenterology, Oklahoma University Health Sciences Center, Oklahoma City, Oklahoma, USA
| | | | | | | | | | | | | | | | | |
Collapse
|
43
|
Yilmaz M, Camci C, Sari I, Okan V, Sevinc A, Onat AM, Buyukhatipoglu H. Histiocytic necrotizing lymphadenitis (Kikuchi-Fujimoto's disease) mimicking systemic lupus erythematosus: a review of two cases. Lupus 2007; 15:384-7. [PMID: 16830886 DOI: 10.1191/0961203306lu2320cr] [Citation(s) in RCA: 32] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
Kikuchi-Fujimoto's disease (KFD), or histiocytic necrotizing lymphadenitis, is a benign and self-limited lymphadenitis commonly found in young women. It often shares clinical features with systemic lupus erythematosus (SLE), such as arthralgias, fever and leukopenia. The etiology of KFD remains unknown and controversial. Clinical course is favorable, with spontaneous remission in less than four months in almost all cases. Herein, we present two cases. The former is a 53-year old woman presenting with cervical lymphadenopathy, arthralgia, pancytopenia and positive antinuclear antibody (ANA). Lymph node biopsy revealed histopathological features compatible with Kikuchi-Fujimoto histiocytic necrotizing lymphadenitis. The latter patient was a 20-year old woman presenting with left cervical lympadenopathy, a butterfly rash that was reminiscent of SLE, and a positive antinuclear antibody. Based upon clinical, histological and laboratory findings, the diagnosis of SLE was excluded. Careful attention should be paid to differentiating between KFD and SLE, because of their similar presentations, yet different clinical courses and therapeutic requirements.
Collapse
Affiliation(s)
- M Yilmaz
- Department of Hematology, Gaziantep University, School of Medicine, Gaziantep, Turkey
| | | | | | | | | | | | | |
Collapse
|
44
|
Akdogan M, Camci C, Gurakar A, Gilcher R, Alamian S, Wright H, Nour B, Sebastian A. The effect of total plasma exchange on fulminant hepatic failure. J Clin Apher 2006; 21:96-9. [PMID: 16142721 DOI: 10.1002/jca.20064] [Citation(s) in RCA: 52] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
Abstract
Total plasma exchange (TPE) corrects coagulopathy in patients with liver disease and removes hepatotoxins/cytokines. This improvement is transient but can be used as a bridge until an organ is identified for liver transplantation (LTx) or the liver itself regenerates. Our aim was to retrospectively assess the efficacy of TPE in fulminant hepatic failure (FHF) and its impact on liver function tests. Between 1995-2001, 39 patients with FHF who had undergone TPE were reviewed. FHF was defined according to the O'Grady criteria based on the duration of encephalopathy as well as jaundice. TPE was performed using the Cobe Spectra TPE (Gambro) in Liver Intensive Care Unit, continued on a daily basis, until either adequate clinical response was achieved, the patient expired, or transplantation occurred. INR, PTT, Fibrinogen, ALT, AST, GGT, BUN, Ammonia, and Total Bilirubin were analyzed before and after TPE. Student's t-test and chi-square test and ANOVA were used for statistical analysis. Thirty-nine patients with FHF (31 females, 8 males with mean age of 32.3, range: 7-64) underwent TPE. Coagulopathy, hyperbilirubinemia, hyperammonemia were significantly improved (P < 0.05). Twenty-one patients survived (54%), 12 required LTx, and 18 patients (including one after LTx) expired. TPE was found to be significantly effective for correction of coagulopathy and improvement of liver tests. This intervention can be considered for temporary liver support until recovery or liver transplantation.
Collapse
Affiliation(s)
- M Akdogan
- Nazih Zuhdi Transplant Institute, INTEGRIS Baptist Medical Center, Oklahoma City, OK 73120, USA
| | | | | | | | | | | | | | | |
Collapse
|
45
|
Buyukhatipoglu H, Sevinc A, Camci C, Buyukberber S, Sari I. A case representing coexistence of acute myeloblastic leukemia and dedifferentiated liposarcoma: the possible role of chemotherapy in triggering dedifferentiation. ACTA ACUST UNITED AC 2006; 28:343-6. [PMID: 16999727 DOI: 10.1111/j.1365-2257.2006.00806.x] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
Acute myelogenous leukemia (AML) is a hematological disorder that is characterized by an abnormal proliferation of immature myeloid cells. Dedifferentiated and well-differentiated liposarcomas are the two pathological subtypes of liposarcoma, based on the WHO classification. Transition from well-differentiated to dedifferentiated liposarcoma is a well-recognized phenomenon. Well-differentiated tumors are known to have low malignancy grade. However, when dedifferentiation occurs, the tumor acquires the aggressive features of a fully malignant lesion. This process largely is believed to progress in a time-dependant manner; however, time is not the only factor of importance. The potential roles of other factors in this transition are still unclear. To date, the coexistence of AML and liposarcoma has not been reported in the literature. In this paper, we report on a case of coexistence of AML and liposarcoma, and on the unusual behavior of a well-differentiated tumor after dedifferentiation occurs.
Collapse
Affiliation(s)
- H Buyukhatipoglu
- Division of Medical Oncology, Gaziantep Oncology Hospital, Gaziantep University, Gaziantep, Turkey
| | | | | | | | | |
Collapse
|
46
|
Camci C, Gurakar A, Rose J, Rizvi S, Wright H, Bader T, Monlux R, Schade RR, Nour BM, Sebastian A. Liver transplantation for hepatitis B in the United States. Transplant Proc 2006; 37:4350-3. [PMID: 16387118 DOI: 10.1016/j.transproceed.2005.10.017] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/07/2005] [Indexed: 01/08/2023]
Abstract
AIM To evaluate the impact of hepatitis B virus (HBV) on US health care system, we reviewed the Organ Procurement and Transplantation (OPTN, formerly UNOS) HBV database. METHOD We reviewed records of liver transplantations (LTx) performed in the United States listed for the diagnoses of HBV between 1993 and mid-October 2004. Both acute as well as chronic cases were included. Coinfection with hepatitis C virus was excluded from study. The specific states selected for review were chosen from those areas that are receiving large numbers of new immigrants from high HBV endemic areas (ie, Texas, Pennsylvania, California, New York, and Florida). One-, 3-, and 5-year patient survival rates for both cadaveric and living related donors were analyzed. Survival rates were obtained from OPTN database as Kaplan-Meyer survival test. RESULTS Between 1993 and mid-October 2004, 53,312 LTx had been performed nationwide. Of these, 2314 (4.34%) were performed for the diagnosis of HBV; 1816 cases (78%) were due to chronic HBV infection (45 of them were living donor LTx) and 498 cases (22%) were due to HBV-induced acute liver failure (seven of them were living donor LTx). Three- and 5-year survival rates of chronic HBV-related LTx patients were better than acute HBV-related and overall LTx patients. CONCLUSION HBV is generally considered to have a minor health significance by many community gastroenterologists. With growing immigration from overseas, it may eventually have a higher impact on LTx. Therefore, it is crucial to further educate gastroenterologists and primary care physicians caring for this specific group of patients.
Collapse
Affiliation(s)
- C Camci
- Nazih Zuhdi Transplant Institute, Integris Baptist Medical Center, Oklahoma City, Oklahoma 73112, USA
| | | | | | | | | | | | | | | | | | | |
Collapse
|
47
|
Abstract
Gastric cancer (GCa) is still a common cause of cancer-related deaths worldwide, despite improved diagnostic and therapeutic implications. Hence, early diagnosis has critical importance. Flow cytometry reveals rapid and reproducible quantification of nuclear DNA content of disaggregated tissues and assessment of its significance in various malignant and precancerous lesions. A total of 121 patients with GCa, chronic atrophic gastritis (CAG), gastric polyps, intestinal metaplasia (IM) and gastric dysplasia and 36 healthy controls were enrolled in this study. Flow cytometric measurements of DNA ploidy, total S-phase, G2M-phase and proliferative indexes (PIs) were analysed on fresh gastric biopsy specimens obtained by gastroscopy. DNA aneuploidy was present in 43.75% of the GCas (p < 0.05). We found a DNA aneuploidy rate of 15.38% in CAG, 15.38% in IM and 25% in epithelial dysplasia. One of nine polyps had aneuploidy. None of the normal gastric mucosa samples showed aneuploidy. The controls had lower rates of total S-phase and PIs (p < 0.05). In conclusion, DNA flow cytometry may be offered as an objective diagnostic tool for early detection of malignant transformation in gastric lesions.
Collapse
Affiliation(s)
- M H Yasa
- Department of Gastroenterology, School of Medicine, Ondokuz Mayis University, Samsum, Turkey.
| | | | | | | | | | | |
Collapse
|
48
|
Camci C, Akdogan M, Gurakar A, Gilcher R, Rose J, Monlux R, Alamain S, Wright H, Sebastian A, Nour B. The impact of total plasma exchange on early allograft dysfunction. Transplant Proc 2005; 36:2567-9. [PMID: 15621091 DOI: 10.1016/j.transproceed.2004.09.071] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/08/2023]
Abstract
INTRODUCTION Early allograft dysfunction (EAD) is a rare but serious complication encountered among patients undergoing liver transplant surgery. Total plasma exchange (TPE) in EAD has been suggested, but its role is still considered investigational. We retrospectively assessed the efficacy of TPE in EAD and its impact on other parameters of liver function. MATERIALS AND METHODS Between 1995 and 2001, 25 orthotopic liver transplant recipients developed EAD, which was defined as early postoperative prothrombin time (PT) >17 seconds, aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) >2500 IU/L, and/or the presence of hepatic encephalopathy, and development of renal failure. Daily TPE was performed using the Cobe Spectra TPE (Gambro) for 4 hours until an adequate clinical response, the patient underwent retransplantation, or the patient died. International normalizing ratio (INR), partial thromboplastin time (PTT), fibrinogen, ALT, AST, gamma-glutanyl transpeptidase (GGT), blood urea nitrogen (BUN), ammonia, and total bilirubin were analyzed before and after TPE. Student t and chi-square tests were used for statistical analysis. RESULTS Twenty-five patients with EAD included 13 females, 12 males of mean age 42.3 years (range, 1-63 years). Coagulopathy and hyperbilirubinemia significantly improved with TPE. Nineteen patients (76%) survived and 2 required retransplantation. Mean number of TPE sessions was 4.3. CONCLUSION TPE was effective to correct coagulopathy and improve liver function. These results suggest the benefit of potential temporary liver support until recovery or retransplantation, in the absence of sepsis or multi-system organ failure.
Collapse
Affiliation(s)
- C Camci
- Integris Baptist Medical Center
| | | | | | | | | | | | | | | | | | | |
Collapse
|
49
|
|
50
|
Ozdarendeli A, Camci C, Aygen E, Kirkil C, Toroman ZA, Dogru O, Doymaz MZ. SV40 in human thyroid nodules. J Clin Virol 2004; 30:337-40. [PMID: 15163424 DOI: 10.1016/j.jcv.2003.12.008] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Revised: 12/12/2003] [Accepted: 12/23/2003] [Indexed: 11/21/2022]
Abstract
BACKGROUND Simian virus 40 (SV40) has been a model experimental system for the study of cell transformation and tumorigenesis for many years. The study of SV40 in humans has aroused interest in the related BK virus (BKV) and JC virus (JCV) and their role in human disease. OBJECTIVES SV40 has been found in a variety of human samples, both malignant and normal. Many independent studies have suggested that SV40 plays a role for some cancers. However, in most cases the role of SV40 remains unclear. STUDY DESIGN The subject of this study consisted of 99 patients with thyroid nodules. Both thyroid nodule and normal thyroid tissue were taken from each patient to test whether they contained SV40 sequences. RESULTS We detected SV40 sequences by polymerase chain reaction (PCR) in four of 99 thyroid nodules. Two of them were papillary thyroid carcinomas and the others were benign thyroid nodules. No SV40 was detected in 99 of normal thyroid tissues of the same patients. DNA sequence analysis, performed in four positive samples, confirmed that PCR products belong to the SV40 T antigen (Tag) region. CONCLUSION The possible role of SV40 in the development of thyroid nodules and the spread of SV40 by horizontal infection in the human population are discussed.
Collapse
Affiliation(s)
- A Ozdarendeli
- Department of Microbiology and Clinical Microbiology, College of Medicine, Firat University, Elazig, Turkey.
| | | | | | | | | | | | | |
Collapse
|